FR13C0016I1 - - Google Patents

Info

Publication number
FR13C0016I1
FR13C0016I1 FR13C0016C FR13C0016I1 FR 13C0016 I1 FR13C0016 I1 FR 13C0016I1 FR 13C0016 C FR13C0016 C FR 13C0016C FR 13C0016 I1 FR13C0016 I1 FR 13C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22495168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0016(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0016I1 publication Critical patent/FR13C0016I1/fr
Application granted granted Critical
Publication of FR13C0016I2 publication Critical patent/FR13C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Packages (AREA)
FR13C0016C 1999-06-25 2013-03-08 Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps Active FR13C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14131699P 1999-06-25 1999-06-25
PCT/US2000/017366 WO2001000245A2 (fr) 1999-06-25 2000-06-23 Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps

Publications (2)

Publication Number Publication Date
FR13C0016I1 true FR13C0016I1 (fr) 2013-04-12
FR13C0016I2 FR13C0016I2 (fr) 2014-05-16

Family

ID=22495168

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0016C Active FR13C0016I2 (fr) 1999-06-25 2013-03-08 Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps

Country Status (33)

Country Link
EP (2) EP1189641B1 (fr)
JP (2) JP4283474B2 (fr)
KR (2) KR100850389B1 (fr)
CN (4) CN101121021B (fr)
AR (1) AR024464A1 (fr)
AT (2) AT500848B1 (fr)
AU (2) AU784045B2 (fr)
BE (1) BE2013C020I2 (fr)
BR (2) BR122014028365B8 (fr)
CA (2) CA2727172A1 (fr)
CH (1) CH694589A5 (fr)
CY (2) CY1109525T1 (fr)
CZ (1) CZ299702B6 (fr)
DE (2) DE60042648D1 (fr)
DK (1) DK1189641T5 (fr)
ES (1) ES2329437T3 (fr)
FR (1) FR13C0016I2 (fr)
GB (1) GB2368796B (fr)
GE (1) GEP20104998B (fr)
HK (1) HK1044888A1 (fr)
HU (1) HU226742B1 (fr)
IL (3) IL146954A0 (fr)
LU (1) LU92164I2 (fr)
MX (1) MXPA01013458A (fr)
NO (3) NO328377B1 (fr)
NZ (2) NZ516830A (fr)
PL (2) PL204629B1 (fr)
PT (1) PT1189641E (fr)
RU (2) RU2270029C2 (fr)
SI (3) SI2283867T1 (fr)
TR (1) TR200103756T2 (fr)
WO (1) WO2001000245A2 (fr)
ZA (2) ZA200109786B (fr)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
BRPI0012196B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
WO2001000245A2 (fr) * 1999-06-25 2001-01-04 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
WO2001024763A2 (fr) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
US20020064785A1 (en) 2000-05-19 2002-05-30 Genentech Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
EP1228766A1 (fr) * 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
AT500649A1 (de) * 2001-10-26 2006-02-15 Altarex Medical Corp Kombinationstherapie zur krankheitsbehandlung
US7585491B2 (en) * 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CA2481509A1 (fr) * 2002-04-11 2003-10-23 Suzanna Tatarewicz Molecules de tyrosine kinase du recepteur her-2 et utilisations associees
ITTO20020340A1 (it) * 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NO340576B1 (no) * 2002-07-11 2017-05-15 Hoffmann La Roche Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
DK1585966T3 (da) 2002-07-15 2012-02-20 Hoffmann La Roche Behandling af cancer med anti-ErbB2-antistoffet rhuMab 2C4
WO2004009112A1 (fr) 2002-07-18 2004-01-29 Helix Biopharma Corp. Utilisation d'urease pour inhiber la croissance de cellules cancereuses
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003248982B2 (en) * 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP4790413B2 (ja) * 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
JP2007517767A (ja) * 2003-03-11 2007-07-05 ダナ ファーバー キャンサー インスティテュート ウイルスの病原性の阻害方法
KR100872210B1 (ko) * 2003-04-23 2008-12-05 메다렉스, 인코포레이티드 인터페론 알파 수용체-1 (ｉｆｎａｒ-1)에 대한 인체화항체
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SI1648940T1 (sl) 2003-07-28 2016-08-31 Genentech, Inc. Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
WO2005020923A2 (fr) * 2003-08-29 2005-03-10 Cedars-Sinai Medical Center Composition et methode pour le traitement de cancers et d'autres troubles physiologiques, fondees sur la regulation de la voie ppar-gamma et de l'axe de la her-kinase
EP1664082B1 (fr) * 2003-09-18 2014-03-05 MacroGenics West, Inc. Kid3 et anticorps dirigés contre kid3
KR20070003806A (ko) * 2003-11-28 2007-01-05 미트라 메디컬 아베 Ｅｒｂ 항원의 표적화
EP1753463A2 (fr) * 2004-06-01 2007-02-21 Genentech, Inc. Conjugues de medicaments anticorps et procedes correspondants
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
KR20170054551A (ko) 2004-07-22 2017-05-17 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (fr) * 2004-12-07 2006-06-15 Genentech, Inc. Selection de patients pour une therapie avec un inhibiteur de her
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
RS53128B (en) 2005-02-23 2014-06-30 Genentech Inc. Extending the time of disease progression or survival in patients with ovarian cancers using PERTUZUMAB
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007021423A2 (fr) 2005-08-15 2007-02-22 Genentech, Inc. Disruptions et compositions geniques et procedes associes
KR101164820B1 (ko) 2005-09-22 2012-07-12 삼성전자주식회사 디스플레이장치
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2008036437A2 (fr) 2006-04-19 2008-03-27 Genentech, Inc. Nouvelles disruptions génétiques, compositions et procédés les concernant
CN103030696B (zh) 2006-05-30 2016-09-28 健泰科生物技术公司 抗体和免疫偶联物及其用途
MX2008015581A (es) * 2006-06-05 2008-12-17 Genentech Inc Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
SG174090A1 (en) 2006-08-21 2011-09-29 Hoffmann La Roche Tumor therapy with an anti-vegf antibody
WO2008031531A1 (fr) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Thérapie antitumorale avec une combinaison d'anticorps anti-her2
CN103396486A (zh) * 2006-10-12 2013-11-20 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
PL2845866T3 (pl) 2006-10-27 2017-10-31 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowanie
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2069795A4 (fr) * 2007-06-18 2010-10-06 Medimmune Llc Traitement synergique de cellules qui expriment epha2 et erbb2
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
EP3441402A1 (fr) 2007-10-30 2019-02-13 Genentech, Inc. Purification d'anticorps par chromatographie à échange de cations
JP2011504740A (ja) * 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
WO2009088805A2 (fr) 2008-01-03 2009-07-16 The Scripps Research Institute Ciblage d'anticorps par domaine de reconnaissance modulaire
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
HUE029869T2 (en) 2008-01-31 2017-04-28 Genentech Inc Anti-CD79B antibodies and immunoconjugates, as well as application procedures
KR101881168B1 (ko) 2008-03-14 2018-07-24 제넨테크, 인크. 약물 저항성과 관련된 유전적 변이
MY188477A (en) * 2008-03-18 2021-12-13 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
KR20110076918A (ko) 2008-09-10 2011-07-06 제넨테크, 인크. 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
CN102471380B (zh) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 抗FcRH5抗体和免疫偶联物及使用方法
SG175078A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
EP2435071A1 (fr) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
AU2010284446A1 (en) * 2009-08-15 2012-03-08 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
PL2473617T3 (pl) 2009-09-01 2020-06-29 F. Hoffmann-La Roche Ag Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
TW201122101A (en) * 2009-10-28 2011-07-01 Facet Biotech Corp Anti-EGFR antibodies and their uses
EP2496601B1 (fr) 2009-11-05 2017-06-07 F. Hoffmann-La Roche AG Methodes et compositions pour la secretion de polypeptides heterologous
DK2719708T3 (da) 2009-11-13 2018-01-29 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
WO2011069104A2 (fr) 2009-12-04 2011-06-09 Genentech, Inc. Anticorps plurispécifiques, analogues d'anticorps, compositions et procédés
MX340014B (es) * 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MY160556A (en) * 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
TR201905081T4 (tr) 2010-03-22 2019-05-21 Hoffmann La Roche Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler.
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2011147986A1 (fr) 2010-05-27 2011-12-01 Genmab A/S Anticorps monoclonaux contre her2
CA2800769C (fr) 2010-05-27 2021-11-02 Genmab A/S Anticorps monoclonaux contre l'epitope de her2
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
CA2795972A1 (fr) 2010-06-03 2011-12-08 Genentech, Inc. Imagerie par immuno-tep d'anticorps et d'immunoconjugues et utilisations correspondantes
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
EP3586826B1 (fr) 2010-06-24 2021-05-12 F. Hoffmann-La Roche AG Compositions et procédés de stabilisation de formulations contenant des protéines
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
CN103380144B (zh) 2010-12-21 2016-03-02 霍夫曼-拉罗奇有限公司 同等型富集的抗体制备物及其获得方法
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
EP2655414B1 (fr) 2010-12-23 2018-08-29 Roche Diagniostics GmbH Agent de liaison bispécifique
PT2670753T (pt) 2011-01-31 2017-01-10 Novartis Ag Novos derivados heterocíclicos
CN103649326B (zh) * 2011-03-08 2016-08-17 宾夕法尼亚大学理事会 用于治疗和诊断用途的抗体样蛋白
CA2832389A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispecifiques contre her2 et cd3
EP2714738B1 (fr) 2011-05-24 2018-10-10 Zyngenia, Inc. Complexes plurispécifiques multivalents et monovalents, et leurs utilisations
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
JP2015506955A (ja) 2012-01-31 2015-03-05 スミスクライン ビーチャム （コーク） リミテッド がんを治療する方法
EP2638916A1 (fr) 2012-03-16 2013-09-18 Covagen AG Nouvelles molécules de liaison ayant une activité antitumorale
WO2013148315A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
KR101505157B1 (ko) * 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
EP2849756A1 (fr) 2012-05-16 2015-03-25 Novartis AG Régime posologique pour un inhibiteur de pi-3 kinase
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US20150329524A1 (en) 2013-01-10 2015-11-19 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN104628846B (zh) 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
RU2656161C1 (ru) 2013-11-19 2018-05-31 Ремеджен, Лтд. Анти-неr2 антитело и его конъюгат
US10947319B2 (en) 2013-11-27 2021-03-16 Zymeworks Inc. Bispecific antigen-binding constructs targeting HER2
EP3076969B1 (fr) 2013-12-06 2021-09-01 Novartis AG Schéma posologique d'un inhibiteur de la phosphatidylinositol 3-kinase sélectif de l'isoforme alpha
ES2727351T3 (es) 2014-01-31 2019-10-15 Daiichi Sankyo Co Ltd Conjugado de fármaco-anticuerpo dirigido contra HER2
WO2015128837A1 (fr) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
JP6644717B2 (ja) 2014-03-14 2020-02-12 ジェネンテック， インコーポレイテッド 異種ポリペプチドを分泌させるための方法及び組成物
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
EP3388449A3 (fr) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Anticorps et conjugués modifies génetiquement avec de la cystéine
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CA2984458A1 (fr) * 2015-05-13 2016-11-17 Zymeworks Inc. Constructions de liaison a un antigene ciblant her2
EP3331919A1 (fr) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Polythérapie comprenant des anticorps anti-ctla-4
BR112018007422A2 (pt) * 2015-10-13 2018-10-30 Siwa Corp anticorpos anti-age e métodos de uso dos mesmos
KR20180073674A (ko) 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CA3006934A1 (fr) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combinaison d'anticorps ciblant bcma, pd-1 et ox40 dans les traitements de cancers et utilisations connexes
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
CN105646704B (zh) * 2015-12-28 2019-11-15 广西医科大学 抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
EP3337829B1 (fr) 2016-02-19 2020-01-08 Siwa Corporation Procédé et composition pour traiter le cancer, détruire les cellules cancéreuses métastatiques et prévenir la métastase cancéreuse en utilisant des anticorps contre les produits terminaux de glycation avancée (age)
WO2017160990A1 (fr) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein er+, her2-hrg+ à l'aide de traitements d'association comportant un anticorps anti-erbb3
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
EP3454863A1 (fr) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Polythérapies pour le traitement du cancer
WO2017196263A1 (fr) * 2016-05-12 2017-11-16 Agency For Science, Technology And Research Anticorps anti-erbb2 et utilisations correspondantes
EP3475306A1 (fr) 2016-06-23 2019-05-01 Siwa Corporation Vaccins pour l'utilisation dans le traitement de diverses maladies et troubles
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
JPWO2018066626A1 (ja) 2016-10-07 2019-07-18 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
JP7069476B2 (ja) * 2017-01-06 2022-05-18 博奥信生物技▲術▼（南京）有限公司 ＥｒｂＢ２抗体およびその使用
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
EP3589661B1 (fr) 2017-03-02 2023-11-01 Genentech, Inc. Traitement par adjuvants du cancer du sein her2 positif
WO2018175752A1 (fr) 2017-03-22 2018-09-27 Genentech, Inc. Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3609923A1 (fr) 2017-04-13 2020-02-19 Siwa Corporation Anticorps monoclonal humanisé de produit final de glycation avancée
WO2018222135A1 (fr) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancérothérapie
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
US20210128741A1 (en) 2017-08-23 2021-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate preparation and lyophilization for same
EP3677568A4 (fr) 2017-08-31 2021-05-12 Daiichi Sankyo Company, Limited Nouveau procédé de production d'un conjugué anticorps-médicament
CA3073924C (fr) 2017-08-31 2023-10-17 Daiichi Sankyo Company, Limited Procede ameliore de production d'un conjugue anticorps-medicament
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
EP3560945A1 (fr) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Procédés de purification de polypeptides utilisant des polysorbates
EP3804764A4 (fr) 2018-05-28 2022-04-06 Daiichi Sankyo Company, Limited Traitement du cancer à her2 muté par administration d'un conjugué anticorps anti-her2-médicament
CA3106995A1 (fr) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Traitement de la toux chronique, de l'essoufflement ou de la dyspnee a l'aide de compositions de nalbuphine
BR112021001194A2 (pt) 2018-07-25 2021-04-27 Daiichi Sankyo Company, Limited métodos para produzir um conjugado anticorpo-fármaco e para produzir uma composição farmacêutica
JP7406488B2 (ja) 2018-07-27 2023-12-27 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
TWI822822B (zh) 2018-07-31 2023-11-21 日商第一三共股份有限公司 抗體-藥物結合物之用途
US20210290775A1 (en) 2018-08-06 2021-09-23 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and tubulin inhibitor
JP7481255B2 (ja) 2018-08-23 2024-05-10 第一三共株式会社 抗体薬物複合体の感受性マーカー
KR20210064325A (ko) 2018-09-25 2021-06-02 에이비에스씨아이, 엘엘씨 단백질 정제 방법
WO2020084503A1 (fr) 2018-10-26 2020-04-30 Cadila Healthcare Limited Composition comprenant un anticorps ayant un niveau réduit de variants basiques de celui-ci
AU2019396895A1 (en) 2018-12-11 2021-07-08 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN113795512A (zh) 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
AU2020254582A1 (en) 2019-04-01 2021-09-30 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN112007169B (zh) * 2019-05-30 2022-03-08 湖南大学 一种核酸适配体药物偶联物及其制备方法和用途
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
MX2021015651A (es) 2019-06-26 2022-06-14 Glaxosmithkline Ip Dev Ltd Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
CN110551214A (zh) * 2019-08-27 2019-12-10 杨澜 一种人源化抗Periostin单克隆抗体、及其制备方法和应用
CA3167689A1 (fr) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Traitements combines et utilisations et methodes associees
WO2021260582A1 (fr) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur d'aurora b
BR112022026205A2 (pt) 2020-06-24 2023-03-14 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor de atr na fabricação de um medicamento, e, método de tratamento do câncer
WO2021260583A1 (fr) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk
CN116615248A (zh) 2020-06-24 2023-08-18 阿斯利康(英国)有限公司 抗体-药物缀合物和cdk9抑制剂的组合
US20230256110A1 (en) 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
KR20230042055A (ko) 2020-07-20 2023-03-27 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합
MX2023004047A (es) 2020-10-09 2023-04-27 Astrazeneca Uk Ltd Combinacion de conjugado de anticuerpo-farmaco e inhibidor selectivo de poli(adp-ribosa)polimerasas 1 (parp1).
IL302812A (en) 2020-11-11 2023-07-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate combinations with anti-SIRP alpha antibody
WO2023100829A1 (fr) 2021-11-30 2023-06-08 第一三共株式会社 Anticorps musc dégradable par la protéase
TW202333800A (zh) 2021-12-28 2023-09-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及rasg12c抑制劑之組合
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용
WO2023209591A1 (fr) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2
WO2023218378A1 (fr) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Association combinant un anticorps spécifique d'un antigène tumoral et un inhibiteur de cd47
WO2024023750A1 (fr) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0171407B1 (fr) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Ameliorations relatives aux facteurs de croissance
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (fr) 1988-09-23 1996-03-13 Cetus Oncology Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
WO1990014357A1 (fr) 1989-05-19 1990-11-29 Genentech, Inc. Domaine extracellulaire de her2
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
ATE135373T1 (de) 1989-09-08 1996-03-15 Univ Johns Hopkins Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (fr) * 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
WO1993016177A1 (fr) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogeneisation de ciblages de genes
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2134773A1 (fr) 1992-06-04 1993-12-09 Robert J. Debs Methodes et compositions pour genotherapie in vivo
JPH08504172A (ja) 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
CA2140280A1 (fr) 1992-08-17 1994-03-03 Avi J. Ashkenazi Immunoadhesines bispecifiques
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2103323A1 (fr) 1992-11-24 1994-05-25 Gregory D. Plowman Tyrosine kinase du recepteur her4 humain
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP1241264A1 (fr) 1994-12-02 2002-09-18 Chiron Corporation Anticorps monoclonaux diriges contre des antigenes associes au carcinome du colon
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
CA2222231A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
WO1997000271A1 (fr) 1995-06-14 1997-01-03 The Regents Of The University Of California Nouveaux anticorps humains a forte affinite diriges contre des antigenes tumoraux
WO1997004801A1 (fr) 1995-07-27 1997-02-13 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA2257839C (fr) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-hereguline
KR100539030B1 (ko) * 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법
EP0931147A1 (fr) * 1996-10-18 1999-07-28 Genentech, Inc. ANTICORPS ANTI-ErbB2
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999019488A1 (fr) 1997-10-15 1999-04-22 Children's Medical Center Corporation Nouveaux recepteurs humains de l'egf et leur utilisation
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
DE60040981D1 (de) * 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
WO2001000245A2 (fr) * 1999-06-25 2001-01-04 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
BRPI0012196B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc artigo industrializado
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar

Also Published As

Publication number Publication date
KR100850389B1 (ko) 2008-08-04
IL146954A (en) 2009-09-22
RU2005132788A (ru) 2007-04-27
PL352321A1 (en) 2003-08-11
CZ299702B6 (cs) 2008-10-22
CN101121021A (zh) 2008-02-13
BRPI0012198B8 (pt) 2021-05-25
HU226742B1 (en) 2009-08-28
CN101121021B (zh) 2011-12-07
EP1189641A2 (fr) 2002-03-27
GB2368796B (en) 2004-08-04
HUP0201695A2 (en) 2002-09-28
EP2112167A3 (fr) 2010-12-22
CZ20014596A3 (cs) 2003-02-12
ZA200109786B (en) 2002-11-28
AT500848A1 (de) 2006-04-15
RU2270029C2 (ru) 2006-02-20
MXPA01013458A (es) 2002-07-30
NO20016329L (no) 2002-02-25
NO328377B1 (no) 2010-02-08
NZ516830A (en) 2004-07-30
WO2001000245A3 (fr) 2001-10-25
NO20016329D0 (no) 2001-12-21
BR122014028365B1 (pt) 2020-01-28
BR122014028365B8 (pt) 2021-07-06
CN101518653A (zh) 2009-09-02
DK1189641T3 (da) 2009-11-16
NO336040B1 (no) 2015-04-27
KR100797308B1 (ko) 2008-01-23
KR20070094993A (ko) 2007-09-27
AT500848B1 (de) 2008-01-15
GB2368796A (en) 2002-05-15
IL146954A0 (en) 2002-08-14
TR200103756T2 (tr) 2002-06-21
CH694589A5 (de) 2005-04-15
PL204629B1 (pl) 2010-01-29
DE10084743T1 (de) 2002-08-14
IL197359A0 (en) 2011-07-31
SI1189641T1 (sl) 2009-12-31
BE2013C020I2 (fr) 2019-08-21
EP2112167A2 (fr) 2009-10-28
DE60042648D1 (de) 2009-09-10
JP2003503366A (ja) 2003-01-28
ZA200110263B (en) 2003-02-26
BR0012198A (pt) 2002-04-02
CA2727172A1 (fr) 2001-01-04
JP2009142280A (ja) 2009-07-02
CY1109525T1 (el) 2014-08-13
KR20020068264A (ko) 2002-08-27
HK1044888A1 (en) 2002-11-08
NO2013005I1 (no) 2013-04-02
WO2001000245A2 (fr) 2001-01-04
ATE437655T1 (de) 2009-08-15
ES2329437T3 (es) 2009-11-26
NZ531426A (en) 2005-10-28
AU2005242195A1 (en) 2006-01-12
AR024464A1 (es) 2002-10-02
NO2013005I2 (no) 2013-03-12
CN101518653B (zh) 2015-08-19
CY2013010I1 (el) 2015-08-05
RU2430739C2 (ru) 2011-10-10
AU784045B2 (en) 2006-01-19
CN101121750A (zh) 2008-02-13
CN1370082A (zh) 2002-09-18
FR13C0016I2 (fr) 2014-05-16
RU2430739C9 (ru) 2015-12-20
EP1189641B1 (fr) 2009-07-29
SI2283867T1 (sl) 2014-07-31
CA2376596A1 (fr) 2001-01-04
CN100340575C (zh) 2007-10-03
CA2376596C (fr) 2009-10-06
AU2005242195B2 (en) 2009-06-11
AU5763200A (en) 2001-01-31
HUP0201695A3 (en) 2005-06-28
PT1189641E (pt) 2009-11-04
DK1189641T5 (da) 2011-04-11
GB0200506D0 (en) 2002-02-27
PL203326B1 (pl) 2009-09-30
GEP20104998B (en) 2010-06-10
LU92164I2 (fr) 2013-05-07
CY2013010I2 (el) 2015-08-05
BRPI0012198B1 (pt) 2016-12-20
NO20091792L (no) 2002-02-25
SI2283866T1 (sl) 2015-07-31
JP4283474B2 (ja) 2009-06-24

Similar Documents

Publication Publication Date Title
BE2013C020I2 (fr)
BE2013C015I2 (fr)
BE2013C001I2 (fr)
BE2012C036I2 (fr)
BE2011C004I2 (fr)
BE2010C011I2 (fr)
BE1025464I2 (fr)
JP2002522148A5 (fr)
BE2008C046I2 (fr)
BRPI0017527B8 (fr)
BE2008C047I2 (fr)
JP2002511686A5 (fr)
BRPI0001672A2 (fr)
JP2002504459A5 (fr)
JP2002534732A5 (fr)
JP2002524148A5 (fr)
JP2002526991A5 (fr)
JP2002502644A5 (fr)
JP2002514751A5 (fr)
JP2002516741A5 (fr)
JP2002507819A5 (fr)
JP2002501854A5 (fr)
BRPI0012675B8 (fr)
BRPI0017522A2 (fr)
JP2002528833A5 (fr)